Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Generic name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Truxima Rituximab Cancelled
Verzenio Abemaciclib Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete Dec 3, 2018 Jul 5, 2019
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Withdrawn Jul 29, 2019
Zytiga Abiraterone Withdrawn Feb 25, 2019
Zytiga Abiraterone acetate Metastatic Castration Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete Mar 28, 2013 Oct 22, 2013
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Reimburse with clinical criteria and/or conditions Complete Apr 7, 2020 Jan 8, 2021
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete Apr 7, 2020 Nov 17, 2020
Giotrif Afatinib Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse Complete Jun 7, 2013 May 2, 2014
Zaltrap Aflibercept Metastatic Colorectal Cancer Do not reimburse Complete Nov 26, 2013 Sep 5, 2014
Proleukin Aldesleukin (IL-2) In-transit Melanoma Reimburse Complete Jan 30, 2015 Jun 22, 2015